Orexo R&D Day - Building global leadership in amorphous drug delivery
Uppsala, Sweden – March 24, 2026 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) today welcomes investors, analysts and media to attend the company’s R&D Day. The event starts at 9.30 am CET, with registration from 9.00 am, and takes place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
With more than 30 years of experience in drug delivery and multiple products approved globally, Orexo has built a strong scientific heritage. Following the divestment of Zubsolv® in the US, the company has entered a new era as a focused drug delivery company, with the ambition to achieve global leadership in the development of amorphous formulations and to advance powder‑based pharmaceutical development programs across multiple routes of administration. At the core of this strategy is AmorphOX®, a next‑generation platform that enhances bioavailability and stability for both small and large molecules (incl. peptides and vaccine) and enables new approaches to route of administration, manufacturing, and distribution.
During the day, CEO Nikolaj Sørensen and the management team will provide deeper insights into Orexo’s updated strategy and development priorities, including the company’s innovation capabilities, pipeline, and manufacturing expertise.
Presentation materials will be made available on the company’s website when the program starts. A recorded version of all presentations will be published on the website no later than the day after the event.
Agenda for the day see below, and on the R&D Day webpage: https://orexo.com/investors/calendar/2026-03-24-orexo-rd-day-2026/.
| Time am CET | Topic or activity | Presenter |
| 9:00 – 9.30 | Registration and coffee. | |
| 9:30 – 9:45 | Shaping Orexo’s future: Strategic priorities and value creation. | Nikolaj Sørensen, President and CEO. |
| 9:45 – 10:00 | AmorphOX: A unique opportunity to transform drug delivery of biomolecules in an established scalable commercial supply chain. | Robert Rönn, SVP Head of R&D / Cecilia Coupland, SVP Head of Operations. |
| 10:00 – 10:15 | AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships. | Lisa Moore, SVP Product and Portfolio Strategy / Robert Rönn |
| 10:15-10:30 | OX640: Advancing a best‑in‑class nasal epinephrine product with improved stability, bioavailability, and patient convenience, supported by accelerated development and scalable manufacturing. | Lisa Moore / Cecilia Coupland |
| 10:30-10:45 | Break. | |
| 10:45-11:00 | OX390: Developing the world’s first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services. | Edward Kim, Chief Medical Officer. |
| 11:00-11:15 | Expert perspectives: Why counter-measures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations. | Mark A. Smith, PhD Davidson College, NC, US. Dr Smith will attend through a prerecorded video. |
| 11:15-11:30 | Building a viable business model through business development. | Fredrik Järrsten, EVP and CFO, Head of Business Development. |
| 11:30-12:00 | Q&A, incl closing remarks by CEO. | All presenters. |
| 12 pm | Lunch & networking. |
Notes: OX640 is a powder-based intranasal epinephrine product candidate in development for the emergency treatment of Type I allergic reactions; OX390 is a powder-based intranasal rescue medication candidate in development for adulterated overdoses. Neither product has been approved by any regulatory agency.
For further information
Lena Wange, IR and Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.
For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube.
The information was submitted for publication at 7.30 am CET, on March 24, 2026.